ImmunomeIMNM
IMNM
About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Employees: 105
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 28
28% more capital invested
Capital invested by funds: $588M [Q2] → $755M (+$167M) [Q3]
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
4.97% more ownership
Funds ownership: 81.06% [Q2] → 86.03% (+4.97%) [Q3]
2% more funds holding
Funds holding: 112 [Q2] → 114 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
83% less call options, than puts
Call options by funds: $4.72M | Put options by funds: $28.3M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
90%
upside
Avg. target
$26
131%
upside
High target
$30
172%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 90%upside $21 | Overweight Maintained | 14 Nov 2024 |
Stephens & Co. Sudan Loganathan 36% 1-year accuracy 8 / 22 met price target | 172%upside $30 | Overweight Initiated | 8 Nov 2024 |
Financial journalist opinion
Based on 6 articles about IMNM published over the past 30 days
Neutral
Business Wire
23 hours ago
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo.
Neutral
Seeking Alpha
2 days ago
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Can Take The Fight To Competitors With Varegacestat
Neutral
Business Wire
2 days ago
Immunome Announces Pricing of Upsized Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering ex.
Neutral
Business Wire
2 days ago
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-da.
Neutral
Business Wire
2 weeks ago
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 9:45 a.m. PT. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.
Neutral
Business Wire
4 weeks ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company's 2024 Induc.
Positive
MarketBeat
1 month ago
3 Small-Cap Stocks With Big Growth Potential
According to several indicators—including a robust labor market and tamed inflation figures—the U.S. economy heads into 2025 with strong tailwinds. Many of the securities that have been primary beneficiaries of this economic well-being are large-cap (or even mega-cap) titans in the tech industry.
Neutral
Business Wire
2 months ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company's 2024 Inducement Plan. The.
Neutral
Business Wire
2 months ago
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome's management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww.
Negative
Zacks Investment Research
2 months ago
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.
Charts implemented using Lightweight Charts™